Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 12/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | SERPINE1 | P05121 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL545967 | 0.86 | TACR1 (0.43) | TACR1MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL5428175 | 0.82 | TACR1 (0.52) | TACR1SERPINE1 | |
| SCHEMBL27385426 | 0.82 | TACR1 (0.42) | TACR1MEN1KMT2ASERPINE1ALDH1A1 | |
| SCHEMBL20568328 | 0.79 | TACR1 (0.43) | TACR1MEN1KMT2ASERPINE1 | |
| SCHEMBL6678261 | 0.75 | CETP (0.43) | TACR1 | |
| SCHEMBL335254 | 0.75 | MEN1 (0.50) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL30950869 | 0.75 | TACR1 (0.40) | TACR1LMNAALDH1A1 | |
| SCHEMBL788092 | 0.75 | TACR1 (0.40) | TACR1LMNAALDH1A1 | |
| SCHEMBL395409 | 0.75 | MEN1 (0.51) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL545966 | 0.74 | CACNA1G (0.50) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110687-B2 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | disclosed |